Cargando…
Endovascular therapies for hepatic artery stenosis post liver transplantation
PURPOSE: To evaluate primary patency at 12 months after endovascular therapies in hepatic artery stenosis. METHODS: A retrospective review of all endovascular interventions for hepatic artery stenosis (HAS) after liver transplantation that occurred between June 2013 and November 2020 was performed a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729479/ https://www.ncbi.nlm.nih.gov/pubmed/36478229 http://dx.doi.org/10.1186/s42155-022-00338-7 |
_version_ | 1784845478902366208 |
---|---|
author | Khati, I. Jacquier, A. Cadour, F. Bartoli, A. Graber, M. Hardwigsen, J. Tradi, F. Barral, P.-A. |
author_facet | Khati, I. Jacquier, A. Cadour, F. Bartoli, A. Graber, M. Hardwigsen, J. Tradi, F. Barral, P.-A. |
author_sort | Khati, I. |
collection | PubMed |
description | PURPOSE: To evaluate primary patency at 12 months after endovascular therapies in hepatic artery stenosis. METHODS: A retrospective review of all endovascular interventions for hepatic artery stenosis (HAS) after liver transplantation that occurred between June 2013 and November 2020 was performed at a single institution in France. Follow up occurred from 1 month to 4 years (median 15 months). The treatment consisted of dilation with a balloon or stent. We analyzed short-term (technical success and complications) and long-term outcomes (liver function, arterial patency, graft survival at 12 months (GS), and reintervention). We also compared percutaneous balloon angioplasty (PBA) with stent placement. PBA alone was used if < 30% residual stenosis of the hepatic artery was achieved. Stenting was performed if there was greater than 30% residual stenosis and in the case of complications (dissection or rupture). RESULTS: A total of 18 stenoses were suspected on the basis of routine surveillance duplex ultrasound imaging (peak systolic velocity > 200 cm/s, systolic accelerating time > 10 ms and resistive index < 0.5), all of which were confirmed by angio CT, but only 17 were confirmed by angiography. Seventeen patients were included (14 males, mean age 57 years; and three females, mean age 58 years). Interventions were performed in 17 cases (95%) with PBA only (5/17), stent only (5/17) or both (4/17). Immediate technical success was 100%. Major complications occurred in 1 of 17 cases (5.8%), consisting of target vessel dissection. The analysis of the three (groups PBA only, stent only or both) showed the same procedural success (100%), GS (100%) and normal liver function after the procedures but different rates of complications (20% vs. 0% vs. 0%), arterial patency at 12 months (60% vs. 80% vs. 85%) (p = 0.4), early stenosis (40% vs. 80% vs. 0%) or late stenosis (60% vs. 20% vs. 100%) and requirement for reintervention (40% vs. 20% vs. 14%) (p = 0.56). CONCLUSION: This study suggests that PBA, stent, or both procedures show the same primary patency at 12 months. It is probably not a definitive answer, but these treatments are safe and effective for extending graft survival in the context of graft shortages. |
format | Online Article Text |
id | pubmed-9729479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-97294792022-12-09 Endovascular therapies for hepatic artery stenosis post liver transplantation Khati, I. Jacquier, A. Cadour, F. Bartoli, A. Graber, M. Hardwigsen, J. Tradi, F. Barral, P.-A. CVIR Endovasc Original Article PURPOSE: To evaluate primary patency at 12 months after endovascular therapies in hepatic artery stenosis. METHODS: A retrospective review of all endovascular interventions for hepatic artery stenosis (HAS) after liver transplantation that occurred between June 2013 and November 2020 was performed at a single institution in France. Follow up occurred from 1 month to 4 years (median 15 months). The treatment consisted of dilation with a balloon or stent. We analyzed short-term (technical success and complications) and long-term outcomes (liver function, arterial patency, graft survival at 12 months (GS), and reintervention). We also compared percutaneous balloon angioplasty (PBA) with stent placement. PBA alone was used if < 30% residual stenosis of the hepatic artery was achieved. Stenting was performed if there was greater than 30% residual stenosis and in the case of complications (dissection or rupture). RESULTS: A total of 18 stenoses were suspected on the basis of routine surveillance duplex ultrasound imaging (peak systolic velocity > 200 cm/s, systolic accelerating time > 10 ms and resistive index < 0.5), all of which were confirmed by angio CT, but only 17 were confirmed by angiography. Seventeen patients were included (14 males, mean age 57 years; and three females, mean age 58 years). Interventions were performed in 17 cases (95%) with PBA only (5/17), stent only (5/17) or both (4/17). Immediate technical success was 100%. Major complications occurred in 1 of 17 cases (5.8%), consisting of target vessel dissection. The analysis of the three (groups PBA only, stent only or both) showed the same procedural success (100%), GS (100%) and normal liver function after the procedures but different rates of complications (20% vs. 0% vs. 0%), arterial patency at 12 months (60% vs. 80% vs. 85%) (p = 0.4), early stenosis (40% vs. 80% vs. 0%) or late stenosis (60% vs. 20% vs. 100%) and requirement for reintervention (40% vs. 20% vs. 14%) (p = 0.56). CONCLUSION: This study suggests that PBA, stent, or both procedures show the same primary patency at 12 months. It is probably not a definitive answer, but these treatments are safe and effective for extending graft survival in the context of graft shortages. Springer International Publishing 2022-12-08 /pmc/articles/PMC9729479/ /pubmed/36478229 http://dx.doi.org/10.1186/s42155-022-00338-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Khati, I. Jacquier, A. Cadour, F. Bartoli, A. Graber, M. Hardwigsen, J. Tradi, F. Barral, P.-A. Endovascular therapies for hepatic artery stenosis post liver transplantation |
title | Endovascular therapies for hepatic artery stenosis post liver transplantation |
title_full | Endovascular therapies for hepatic artery stenosis post liver transplantation |
title_fullStr | Endovascular therapies for hepatic artery stenosis post liver transplantation |
title_full_unstemmed | Endovascular therapies for hepatic artery stenosis post liver transplantation |
title_short | Endovascular therapies for hepatic artery stenosis post liver transplantation |
title_sort | endovascular therapies for hepatic artery stenosis post liver transplantation |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729479/ https://www.ncbi.nlm.nih.gov/pubmed/36478229 http://dx.doi.org/10.1186/s42155-022-00338-7 |
work_keys_str_mv | AT khatii endovasculartherapiesforhepaticarterystenosispostlivertransplantation AT jacquiera endovasculartherapiesforhepaticarterystenosispostlivertransplantation AT cadourf endovasculartherapiesforhepaticarterystenosispostlivertransplantation AT bartolia endovasculartherapiesforhepaticarterystenosispostlivertransplantation AT graberm endovasculartherapiesforhepaticarterystenosispostlivertransplantation AT hardwigsenj endovasculartherapiesforhepaticarterystenosispostlivertransplantation AT tradif endovasculartherapiesforhepaticarterystenosispostlivertransplantation AT barralpa endovasculartherapiesforhepaticarterystenosispostlivertransplantation |